- Jan-2020: The Percept PC neurostimulator from Medtronic has received the CE mark. BrainSense technology is used in this Deep Brain Stimulation (DBS) device. Patients with neurologic illnesses such as Parkinson's disease can benefit from the system's ability to detect and record brain signals while receiving treatment.
- Jan-2020: The US Food and Drug Administration (FDA) has approved Abbott Laboratories' Infinity Deep Brain Stimulation (DBS) device. This system would be employed in Parkinson's disease treatment. The technology would allow for the improvement of Parkinson's disease symptoms that are not controlled by medication by targeting a specific area of the brain known as the internal globus pallidus (GPi).
Frequently Asked Questions
The market is segmented based on Asia-Pacific Deep Brain Stimulation Systems Market Segmentation, By Product Type (Single-Channel Deep Brain Stimulator, Dual-Channel Deep Brain Stimulator), By Applications (Parkinson's disease, Epilepsy, Essential Tremor, Dystonia, Obsessive Compulsive Disorder and Other Applications), Type (Rechargeable, Non-Rechargeable), By End User (Neurological Clinics, Ambulatory Surgical Centers, Hospital and Others) – Industry Trends and Forecast to 2032
.
The Asia Pacific Deep Brain Stimulation Systems Market size was valued at USD 2.34 USD Billion in 2024.
The Asia Pacific Deep Brain Stimulation Systems Market is projected to grow at a CAGR of 24.3% during the forecast period of 2025 to 2032.
The market report covers data from the China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
